ASHLEIGH CRESSWELL: Open Payments
NPI 1619606308 · FAIRFAX, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$342 in 14 payments from 11 companies in 2025. Trend: 2023 $615 · 2024 $542 · 2025 $342
Food & beverage: $342
| Company | Payments | Amount |
|---|---|---|
| TerSera Therapeutics LLC | 3 | $83 |
| ABBVIE INC. | 2 | $70 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Stemline Therapeutics Inc. | 1 | $27 |
| Incyte Corporation | 1 | $24 |
| Novartis Pharmaceuticals Corporation | 1 | $23 |
| Eisai Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| GlaxoSmithKline, LLC. | 1 | $15 |
Products named: Zoladex, EPKINLY, Enhertu, Orserdu, JAKAFI, KISQALI, Lenvima, Venclexta.
Industry payments across VA — which companies pay providers there.
